Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial

BACKGROUND: People over 60 have been found to develop less protection after two doses of inactivated COVID-19 vaccines than younger people. Heterologous immunisation could potentially induce more robust immune responses compared to homologous immunisation. We aimed to assess the immunogenicity and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Peng-Fei, Guo, Xi-Ling, Gou, Jin-Bo, Hou, Li-Hua, Song, Zhi-Zhou, Zhu, Tao, Pan, Hong-Xing, Zhu, Jia-Hong, Shi, Feng-Juan, Du, Pan, Huang, Hai-Tao, Liu, Jing-Xian, Zheng, Hui, Wang, Xue, Chen, Yin, Wan, Peng, Wu, Shi-Po, Wang, Xue-Wen, Xu, Xiao-Yu, Yan, Fang-Rong, Li, Jing-Xin, Chen, Wei, Zhu, Feng-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281458/
https://www.ncbi.nlm.nih.gov/pubmed/37360864
http://dx.doi.org/10.1016/j.lanwpc.2023.100829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281458/
https://www.ncbi.nlm.nih.gov/pubmed/37360864
http://dx.doi.org/10.1016/j.lanwpc.2023.100829

Ejemplares similares